anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Disclosed herein are compositions and methods for improving the health of a mammal using polysaccharides from Aloe vera. Some aspects relate to methods of improving digestive health in a mammal. Other aspects relate to methods for treating metabolic syndrome in a mammal. Also disclosed herein are methods of separating polysaccharides from Aloe vera. These aloe polysaccharides may be further separated into neutral and acidic polysaccharides. The neutral and acidic polysaccharides may be recombined to form polysaccharides that differ in conformation and size from their unmixed counterparts.
<P>PROBLEM TO BE SOLVED: To provide a new type of a heterocyclic compound, and to provide an application method thereof.  <P>SOLUTION: There is disclosed a compound having a substituted and unsaturated 5-, 6- or 7-membered heterocyclic ring having one or more nitrogen atoms or one or more carbon atoms and having in a ring position adjacent to a ring nitrogen atom a moiety connected to another heterocyclic ring through an alkenylene moiety or an alkynylene moiety. This compound functions as an agonist and an antagonist for receptors in nervous systems and has possible utility in various applications such as regulations of physiological process. Especially, it regulates the activity of excitatory amino acid receptors. Embodiments of applications include methods for regulating metabotropic glutamic acid receptors, and methods for treating and preventing diseases using the heterocyclic compound, for example, methods for treating and preventing diseases in the lung system, diseases in the nervous system, diseases in the cardiovascular system, diseases in the gastrointestinal tract system, diseases in the endocrine system, diseases in the exocrine system, diseases of the skin, cancers, and diseases in the eyeball system.  <P>COPYRIGHT: (C)2011,JPO&INPIT
PD-L1 positive patients will be given Nivolumab 480 mg I.V. over 30 minutes (-/+ 10 minutes) every 4 weeks (every cycle) for 2 a total of 2 cycles.
BACKGROUND: Clinical scenarios frequently present challenges when patients exhibit asymmetrical mandibular atrophy. The dilemma arises: should we adhere to the conventional All-on-4 technique, or should we contemplate placing vertically oriented implants on the side with sufficient bone mass? This study aims to employ three-dimensional finite element analysis to simulate and explore the biomechanical advantages of each approach.
METHODS: A finite element model, derived from computed tomography (CT) data, was utilized to simulate the nonhomogeneous features of the mandible. Three configurations-All-on-4, All-on-5-v and All-on-5-o were studied. Vertical and oblique forces of 200 N were applied unilaterally, and vertical force of 100 N was applied anteriorly to simulate different masticatory mechanisms. The maximum von Mises stresses on the implant and framework were recorded, as well as the maximum equivalent strain in the peri-implant bone.
RESULTS: The maximum stress values for all designs were located at the neck of the distal implant, and the maximum strains in the bone tissue were located around the distal implant. The All-on-5-o and All-on-5-v models exhibited reduced stresses and strains compared to All-on-4, highlighting the potential benefits of the additional implant. There were no considerable differences in stresses and strains between the All-on-5-o and All-on-5-v groups.
CONCLUSIONS: With the presence of adequate bone volume on one side and severe atrophy of the contralateral bone, while the "All-on-4 concept" is a viable approach, vertical implant placement optimizes the transfer of forces between components and tissues.
The present invention relates to health tea which can tranquilize mind, allay excitement and improve sleep. The present invention has the essential technical scheme that the health tea is prepared in a mode that longan pulp, matrimony vine, tuckahoe, sauted spine date seed, multiflower knotweed vine, etc. are mixed in certain proportion, are disinfected, are dried, are broken, are ground and then are respectively subpackaged. The product can make sleep time obviously prolonged, the incidence rate of the sleep is obviously enhanced, and sleep quality can be effectively improved. The health tea takes effect in a short period after being administered. The mind is tranquilized, the heart is nourished, the activity of qi is adjusted, and a life is prolonged after the product is administered. Through longtime administration, the product has the advantages of safety, innocuity, no addiction and no side effect and is called 'sound sleep' tea. The product is suitable for insomniacs and persons with dyssomnia caused by excess cerebration or neurasthenia.
A blinded therapist used an observation-based ergonomics assessment check list for office workers to check the status of office environment, which usually took 40 - 45 minutes to complete. It consists of 5 domains. After assessment required modifications were done in the chair, desk, keyboard, mouse, computer screen, telephone and the office environment. Ergonomic education and instructions were also given on an individual basis as per the report of the assessment.
The present invention relates to a cosmetic composition for preventing hair loss and improving the scalp containing an herbal complex extract. More specifically, a cosmetic composition which is effective in preventing hair loss and improving the scalp is characterized by containing an herbal complex extract. The herbal complex extract is prepared by the steps of: mixing herbal raw materials including Platycladus orientalis, Angelica gigas, Perilla frutescens var. crispa, peppermint, Morus Alba Bark, Houttuynia cordata, and Sophora flavescens, respectively, with extraction solvents and heating and aging the respective extraction solvents; mixing illite with the extraction solvents, and heating, stirring, aging and precipitating the mixed raw materials; and preparing respective herbal raw material extracts by filtering and centrifuging the heated and aged raw materials, respectively, several times and mixing the respective centrifuged herbal raw material extracts. The cosmetic composition according to the present invention contains the herbal complex extract obtained by extracting herbal raw materials including Platycladus orientalis, Angelica gigas, Perilla frutescens var. crispa, peppermint, Morus Alba Bark, Houttuynia cordata, and Sophora flavescens. As such, the cosmetic composition is less irritating to the skin and has stability even when used for a long time, and has excellent hair loss prevention and scalp improvement effects.
A drug delivery device is provided comprising a container, a first product and a second product. The device is configured to mix the first product and the second product with each other within the container for forming a drug mixture. The device is further configured for dispensing the drug mixture. The device comprises a mixing member. The device is switchable from a first state, in which the first product and the second product are separated, into a second state, in which the first product and the second product are mixed. The mixing member is configured to exert a force onto the container in order to move the container to mix the first product and the second product with each other. Furthermore, a method for maintaining a predetermined property of a drug mixture to be dispensed from a drug delivery device is provided.
An apparatus to perform or control obtaining or causing obtaining an image of at least a part of a surface of a sealed unit. The apparatus derives or causes to derive a representation of the at least a part of the surface from the image. The representation includes a set of values representing height levels of corresponding sections of the part of the surface. The apparatus generates or causes generating a string of characters based on the representation of the part of the surface. The string of characters includes a first portion representative of the set of height levels and a second portion generated based on a function of the representation and/or of the first portion of the string of characters. The apparatus associates or causes associating information representing the string of characters with identification information of the sealed unit.
The control group only receiving warfarin therapy (individualized therapy, hence no specific form, dosage, frequency and duration is applicable here - i.e. 5mg daily everyday for 6 months may be applicable to one patient but not all researched patients).
Antitumor agents with a combined use of a tublin polymerization inhibitor having an antitumor activity with an antiinflammatory agent. These two active ingredients may be contained in a single preparation. Alternatively, two preparations containing the respective ingredients to be administered separately may be combined with each other. In case of using a tublin polymerization inhibitor as the active ingredient of an antitumor agent, the toxicity of the tublin polymerization inhibitor at the pharmaceutically effective dose can be largely relieved while maintaining the pharmaceutically effective dose and the fatal dose can be increased to thereby broaden the safety range. Moreover, antitumor methods (treatment methods for the treatment, improvement, inhibition of progress, prevention, etc. of tumor in vivo), use of the above two active ingredients in drugs such as antitumor agents, and combined use of the above two active ingredients as drugs such as antitumor agents either simultaneously or separately.
The employability of the intellectually challenged has received little attention in the past. In order to fill this research gap, the present study was undertaken. The study is centered on the experiences of six intellectually challenged individuals who received employability training at a non-governmental organization. A focus group discussion along with a case study was conducted. The researchers employed the Rigorous and Accelerated Data Reduction (RADaR) technique to analyze the data from the focus group discussion. Results from both the focus group discussion and the case study revealed that the training program has had a significant impact on the lives of the participants and has aided them in becoming economically empowered and independent.
The present disclosure relates to compositions consisting of antimicrobial peptides (AMPs) having an alpha helical structure, wherein one side of the alpha helical structure is highly hydrophobic. Representative sequences of antimicrobial peptides include ilkkwwβαgllgβllgαvβ VIK βlββi (SEQ ID No. 2), lkkkwwkβα KGLLGGLLGKV β VIK (SEQ ID No. 12) and αkkαkkαkgαlgglαgk (SEQ ID No. 18). Additional embodiments disclose treating a microbial infection in a subject in need thereof; reducing biofilm; reducing inflammation; and methods of treating infectious disease, COPD, asthma, pulmonary fibrosis, cystic fibrosis, sinusitis, sepsis, RSV, TB, or cancer, comprising administering to the subject a therapeutic amount of an antimicrobial peptide.
A retrospective cohort study to assess the association between medroxyprogesterone acetate injectable suspension and the incidence of bone fractures was conducted in 312,395 female contraceptive users in the U.K. The incidence rates of fracture were compared between medroxyprogesterone acetate injectable suspension users and contraceptive users who had no recorded use of medroxyprogesterone acetate injectable suspension. The Incident Rate Ratio (IRR) for any fracture during the follow-up period (mean = 5.5 years) was 1.41 (95% CI 1.35, 1.47). It is not known if this is due to medroxyprogesterone acetate injectable suspension use or to other related lifestyle factors that have a bearing on fracture rate.

In the study, when cumulative exposure to medroxyprogesterone acetate injectable suspension was calculated, the fracture rate in users who received fewer than 8 injections was higher than that in women who received 8 or more injections. However, it is not clear that cumulative exposure, which may include periods of intermittent use separated by periods of non-use, is a useful measure of risk, as compared to exposure measures based on continuous use. 

There were very few osteoporotic fractures (fracture sites known to be related to low BMD) in the study overall, and the incidence of osteoporotic fractures was not found to be higher in medroxyprogesterone acetate injectable suspension users compared to non-users. Importantly, this study could not determine whether use of medroxyprogesterone acetate injectable suspension has an effect on fracture rate later in life.
ULORIC (febuxostat) is a xanthine oxidase inhibitor. The active ingredient in ULORIC is 2-[3-cyano-4-(2-methylpropoxy) phenyl]-4-methylthiazole-5-carboxylic acid, with a molecular weight of 316.38. The empirical formula is C16H16N2O3S.

The chemical structure is:

Febuxostat is a non-hygroscopic, white crystalline powder that is freely soluble in dimethylformamide; soluble in dimethylsulfoxide; sparingly soluble in ethanol; slightly soluble in methanol and acetonitrile; and practically insoluble in water. The melting range is 205°C to 208°C.

ULORIC tablets for oral use contain the active ingredient, febuxostat, and are available in two dosage strengths, 40 mg and 80 mg. Inactive ingredients include lactose monohydrate, microcrystalline cellulose, hydroxypropyl cellulose, sodium croscarmellose, silicon dioxide and magnesium stearate. ULORIC tablets are coated with Opadry II, green.
Adverse reactions associated with propafenone occur most frequently in the gastrointestinal, cardiovascular, and central nervous systems. About 20% of patients treated with propafenone have discontinued treatment because of adverse reactions.

Adverse reactions reported for > 1.5% of 474 SVT patients who received propafenone in U.S. clinical trials are presented in the following table by incidence and percent discontinuation, reported to the nearest percent.

Results of controlled trials in ventricular arrhythmia patients comparing adverse reaction rates on propafenone and placebo, and on propafenone and quinidine are shown in the following table. Adverse reactions reported for ≥ 1% of the patients receiving propafenone are shown, unless they were more frequent on placebo than propafenone. The most common events were unusual taste, dizziness, first degree AV block, intraventricular conduction delay, nausea and/or vomiting, and constipation. Headache was relatively common also, but was not increased compared to placebo.

Adverse reactions reported for ≥ 1% of 2,127 ventricular arrhythmia patients who received propafenone in U.S. clinical trials are presented in the following table by propafenone daily dose. The most common adverse reactions in controlled clinical trials appeared dose-related (but note that most patients spent more time at the larger doses), especially dizziness, nausea and/or vomiting, unusual taste, constipation, and blurred vision. Some less common reactions may also have been dose-related such as first degree AV block, congestive heart failure, dyspepsia, and weakness. The principal causes of discontinuation were the most common events and are shown in the table.

In addition, the following adverse reactions were reported less frequently than 1% either in clinical trials or in marketing experience (adverse events for marketing experience are given in italics). Causality and relationship to propafenone therapy cannot necessarily be judged from these events.
FIELD: medicine. ^ SUBSTANCE: invention refers to medicine, namely to rheumatology and physiotherapy. The method involves a contact and labile ultrasound exposure on a joint region. An ultrasound generation mode is used. For the 1-2 procedures, radiation power is 0.2 Wt/cm2, for the 3-4 procedures - 4 Wt/cm2, starting from the 5th procedure - 0.7 Wt/cm2. Each joint is treated for 5 minutes. Total procedure time is 10 minutes. The therapeutic course includes 6-7 daily procedures. A contact medium is presented with the ointment Chondroxide. After the first two procedures, a two-day pause is made. During these days, the joints are covered with the ointment Chondroxide. The following 4-5 procedures are not interrupted. ^ EFFECT: method improves clinical effectiveness, reduces treatment length and allows to avoid unwanted side effect in the form of joint pain intensification and higher arterial pressure during treatment. ^ 1 tbl, 3 ex
COPD is a major cause of morbidity and mortality globally. While the significance of environmental exposures in disease pathogenesis is well established, the functional contribution of genetic factors has only in recent years drawn attention. Notably, many genes associated with COPD risk are also linked with lung function. Because reduced lung function precedes COPD onset, this association is consistent with the possibility that derangements leading to COPD could arise during lung development. In this review, we summarise the role of leading genes (HHIP, FAM13A, DSP, AGER and TGFB2) identified by genome-wide association studies in lung development and COPD. Because many COPD genome-wide association study genes are enriched in lung epithelial cells, we focus on the role of these genes in the lung epithelium in development, homeostasis and injury.
Participants first received Vildagliptin and metformin HCl 50/1000 mg 1 tablet (Test product) in a fasting state. After a washout period of 7 days, they then recieved Galvus Met® 1 tablet (Reference product) in a fed state.
PURPOSE:A pack agent for adsorbing fats and contaminated matters attached to the surface of the skin, having improved adsorbing actions to clean the surface of the skin, comprising a cation resin containing a specific cationic group and a glycol as main agents. CONSTITUTION:A cataplasm comprising a cation resin containing a cationic group shown by the formula I, II, III, or IV (R1 is alkylene, or hydroxyalkylene; R2 and R5  are H or alkyl; R3 and R4 are alkyl; X is inorganic anion; A is amide nitrogen, or  oxygen; n is 1-10) and a glycol as main agents. The cation resin preferably has 0.1-30mol% group shown by the formula II, III, or IV, it is obtained by copolymerizing vinyl acetate, etc. with a compound having the above-mentioned cationic group. Ethylene glycol, glycerol, polyethylene glycol, etc. may be cited as the glycol, and 20-200pts.wt glycol is used with 100pts.wt. cation resin.
Couplers for ultrasound probes can have a solid coupler body and a probe attachment member that is secured to a coupler body. The probe attachment member may extend upwardly from the coupler body. The probe attachment member may frictionally and/or adhesively engage with an ultrasound probe, thereby attaching and/or holding the coupler body to an end of the ultrasound probe. The coupler body may include at least one open channel that that extends through the coupler body to define a fluid path. The at least one open channel may be sized to hold and/or contain a fluid and/or gel in and/or on the coupler body and only release the fluid and/or gel when a force is exerted at a top surface of the coupler body. A coupler may be provided in a package in an orientation and easy to use fashion that may aid in attaching the coupler to an end of an ultrasound probe.
MBCR is a step wise standardized behavioral intervention of MBSR. The program is usually conducted in eight weekly class sessions that are 2-2.5 hours in length. During class sessions, participants are presented with mindfulness meditation techniques and share their experiences related to these meditation practices. There is a home practice component with an expectation of regular home meditation practice of 45 minutes per day. In addition to home meditation practice there are often reading assignments and reflective exercises that relate to mindfulness. A full day retreat generally occurs in the second half of the course, providing an opportunity for class participants to gain extended experience with mindfulness techniques.
The present disclosure relates to RNAi agents, e.g., double stranded RNAi agents, able to inhibit Angiopoietin-like 3 (also called ANGPTL3, ANGPL3, angiopoietin-like protein 3) gene expression, and compositions that include ANGPTL3 RNAi agents. Also disclosed are methods of use of ANGPTL3 RNAi agents and compositions. The ANGPTL3 RNAi agents disclosed herein may be conjugated to targeting ligands to facilitate the delivery to cells, including to hepatocytes. Pharmaceutical compositions that include one or more ANGPTL3 RNAi agents, optionally with one or more additional therapeutics, are described. Deliver}' of the ANGPTL3 RNAi agents in vivo provides for inhibition of ANGPTL3 gene expression, and can result in lower triglycerides and. or cholesterol levels in the subject. The RNAi agents can be used in methods of treatment of ANGPTL3 -related diseases and disorders, including cardiometabolic diseases such as hypertriglyceridemia and hyperlipidemia.
BACKGROUND: Emergence delirium is a complication of pediatric anesthesia during the early recovery period. Children undergoing ear, nose, and throat surgery are at high risk. The Pediatric Assessment of Emergence Delirium (PAED) scale is used for diagnosis and founded to specify the degree of emergence delirium. However, there is no consensus regarding a threshold value for emergence delirium diagnosis. Homeostasis-guided pediatric general anesthesia aims to maintain physiological parameters within normal ranges. In this prospective, observational study we evaluated the incidence of emergence delirium in children undergoing elective ear, nose, and throat surgery under standardized homeostasis-guided general anesthesia. Secondarily, we identified risk factors associated with an increased PAED score.
METHODS: In children aged 0-6 years, we collected data from standard monitoring, depth of anesthesia, and preoperative glucose and ketone body levels. These variables were studied as risk or protective factors for increased PAED >0 scores using multivariate logistic regression.
RESULTS: Of the 105 children analyzed, only five children (4.7%) had emergence delirium according to a threshold PAED score ≥10, while 37 children (35%) had PAED scores >0. Statistical analysis of the PAED outcome identified two significant positive associations with pain (P<0.001) and preoperative blood glucose levels (P=0.006) and one negative association with preoperative ketone body levels (P<0.001).
CONCLUSIONS: Our cohort observed a lower incidence of emergence delirium than in the literature. Higher pain intensity and lower blood glucose levels were risk factors for PAED > 0, whereas preoperative ketone body levels were protective.